Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.
Karim R SaabMeghan J MooradianDaniel Y WangJeewon ChonCathy Y XiaAngelica BialczakKelly T AbbateAlexander M MenziesDouglas B JohnsonRyan J SullivanAlexander N ShoushtariPublished in: Cancer (2018)
The majority of patients receiving BRAF-MEK inhibition after PD-1 therapy require dose interruptions, and a significant minority require hospitalization for AEs. In this higher risk population, the median time receiving therapy and OS may be inferior to those presented in published phase 3 trials.